3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
45
Breast Neoplasms
39
Triple Negative Breast Neoplasms
19
Prostatic Neoplasms
17
Neoplasms
13
Fallopian Tube Neoplasms
13
Endometrial Neoplasms
12
Recurrence
8
Pancreatic Neoplasms
8
Neoplasm Metastasis
8
Squamous Cell Carcinoma of Head and Neck
7
Small Cell Lung Carcinoma
7
Lung Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Glioma
5
Glioblastoma
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Sarcoma
4
Carcinoma, Squamous Cell
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Stomach Neoplasms
3
Solid Tumor
3
Melanoma
3
Head and Neck Neoplasms
3
Fanconi Anemia, Complementation Group D1
3
Uveal Melanoma
2
Uterine Neoplasms
2
Urinary Bladder Neoplasms
2
Interventions
padeliporfin
5
Nivolumab
3
vedolizumab
2
atezolizumab
2
anlotinib
2
Therapeutics
2
Surveys and Questionnaires
2
Riluzole
2
Radiotherapy
2
LDP-02
2
Ipilimumab
2
Infliximab
2
Immunoglobulin G
2
Genetic Testing
2
Fecal Microbiota Transplantation
2
Disulfides
2
Carboplatin
2
CT-P13
2
tislelizumab
1
relatlimab
1
prednylidene
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
ixabepilone
1
ferumoxtran-10
1
enfortumab vedotin
1
deltacortene
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urogenital Neoplasms
×
olaparib
×
Clear all
NCT04566952
2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
68 enrolled